Operator
Greetings, and welcome to the INmune Bio’s 2026 First Quarter Earnings Call. As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.
At this time, it is my pleasure to introduce Mr. Daniel Carlson, Head of Investor Relations of INmune Bio.
Daniel Carlson
Head of Investor Relations
Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio’s 2026 First Quarter Financial Results. Presenting on today’s call are David Moss, CEO and Co-Founder of INmune Bio; Dr. Mark Lowdell, Chief Scientific Officer and Co-Founder of INmune Bio; and Cory Ellspermann, INmune Bio’s CFO.
Before we begin, I remind everyone that except for statements of historical fact, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements involve risks and uncertainties that can cause actual results to differ materially from those such as forward-looking statements. Please see the forward-looking statements disclaimer on the company’s earnings press release as well as risk factors in the company’s SEC filings, including our most recent quarterly filings with the SEC.
There is no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as the facts and circumstances underlying these forward-looking statements may change.
Except as required by law, INmune Bio disclaims any obligation
